Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01015495
Recruitment Status : Withdrawn (Not enough patients within the time frame to allow for a meaningful study.)
First Posted : November 18, 2009
Last Update Posted : July 2, 2012
Genentech, Inc.
Information provided by (Responsible Party):
Jennifer I. Lim, University of Illinois at Chicago

Brief Summary:
The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.

Condition or disease Intervention/treatment Phase
Angioid Streaks Drug: ranibizumab Phase 1 Phase 2

Detailed Description:
Choroidal neovascularization is a hallmark of angioid streaks, and presumably VEGF-driven. Ranibizumab has been shown to be effective in CNV secondary to age-related macular degeneration. Therefore, we hypothesize that ranibizumab may be efficacious in the treatment of CNV secondary to angioid streaks

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ranibizumab Therapy for Choroidal Neovascularization Associated With Angioid Streaks
Study Start Date : December 2009
Estimated Primary Completion Date : December 2010
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arm Intervention/treatment
Experimental: ranibizumab Drug: ranibizumab
0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
Other Name: Lucentis

Primary Outcome Measures :
  1. The primary outcome measures for safety and tolerability are the following: • Incidence and severity of ocular adverse events, as identified by eye examination (including visual acuity testing) [ Time Frame: Month 12 ]

Secondary Outcome Measures :
  1. Proportion of patients that lose fewer than 15 letters from baseline at months 6 and 12 as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters at months 6 and 12 [ Time Frame: Month 6 and 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 18 years
  • Angioid streaks
  • Subfoveal CNV of recent onset with the following characteristics
  • Absence of subfoveal fibrosis
  • Fibrosis less than 25% of the lesion
  • Presence of blood, subretinal fluid, and/or lipid
  • New onset symptoms within 12 weeks
  • Visual acuity 20/40 to 20/800 on an ETDRS chart

Exclusion Criteria:

  • Prior treatment of subfoveal CNV in the study eye
  • Age-related macular degeneration
  • Uncontrolled glaucoma
  • High myopia (> -10.00 D spherical equivalent)
  • Prior retinal detachment
  • Media opacity preventing adequate view of the retina
  • Planned cataract surgery in the next 3 months
  • Current chemotherapy for cancer
  • Immunocompromised state
  • Pregnancy (positive pregnancy test) or lactation
  • Premenopausal women not using adequate contraception.
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
  • Participation in another simultaneous medical investigation or trial
  • History of any previous treatment for angioid streaks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01015495

Sponsors and Collaborators
University of Illinois at Chicago
Genentech, Inc.
Principal Investigator: Jennifer I Lim, MD UIC Eye and Ear Infirmary

Additional Information:
Responsible Party: Jennifer I. Lim, Professor of Ophthalmology, Director of Retina Services, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago Identifier: NCT01015495     History of Changes
Other Study ID Numbers: fvf 3763s
First Posted: November 18, 2009    Key Record Dates
Last Update Posted: July 2, 2012
Last Verified: June 2012

Keywords provided by Jennifer I. Lim, University of Illinois at Chicago:
angioid streaks
intra vitreal ranibizumab

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Angioid Streaks
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Retinal Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents